| Drug | Unique Feature | Key ADR / Concern |
|---|---|---|
| Cimetidine | Think: CYP450 inhibitor + anti-androgen effects. | |
| Ranitidine | Think: withdrawn from market β contamination issue. | |
| Famotidine | Think: most potent Hβ blocker, minimal CYP interactions. |
| PPI | CYP Effects / Notes |
|---|---|
| Omeprazole / Esomeprazole | |
| Pantoprazole | |
| Lansoprazole |
| Feature | PPIs | P-CABs (e.g., Vonoprazan) |
|---|---|---|
| Binding | ||
| Requires Acid Activation? | ||
| Onset | ||
| Meal-Timing Required? |
| Antacid | Key Side Effect | Unique Fact |
|---|---|---|
| Aluminum Hydroxide | Think: binds phosphate in gut β used in CKD hyperphosphatemia. | |
| Magnesium Hydroxide | Think: "Milk of Magnesia" β also used as an osmotic laxative. | |
| Calcium Carbonate | Think: rebound acid + a named syndrome from chronic excess use. | |
| Sodium Bicarbonate | Think: fastest onset + risk of systemic alkalosis and NaβΊ load. |
| Regimen | Drugs (all 4 / all 3) | Duration / When Used |
|---|---|---|
| Quadruple Therapy (preferred, 1st-line) | ||
| Triple Therapy (older, falling out of favor) |
| Drug | MOA | Key Use / Unique Fact | Contraindication / ADR |
|---|---|---|---|
| Sucralfate | Think: requires acidic pH β don't co-administer with PPI/Hβ blocker. | ||
| Misoprostol | Think: PGEβ analog β prevents NSAID ulcers, used in OB for labor induction. | ||
| Bismuth subsalicylate | Think: black stools + black tongue; part of quadruple H. pylori therapy. |
| Category | Examples to List |
|---|---|
| Dietary (β₯4) | |
| Drugs (β₯5 classes) | |
| Systemic disease | |
| Physiologic |
| Center | Location / Feature | Key Receptors | Stimulus |
|---|---|---|---|
| Emetic Center | |||
| CTZ (Area Postrema) | |||
| NTS (Nucleus Tractus Solitarius) | |||
| Vestibular System |
| Class | Prototype Drug(s) | Best Use | Key ADR |
|---|---|---|---|
| 5-HTβ Antagonists | |||
| NKβ Antagonists | |||
| Dβ Antagonists | |||
| Hβ Antagonists | |||
| Mβ Antagonists | |||
| Cannabinoids | |||
| Corticosteroids |
| Drug | MOA (Dual) | Clinical Use | Key ADR / Black Box |
|---|---|---|---|
| Metoclopramide | |||
| Erythromycin |
| Drug | MOA | Key Use / Unique Fact |
|---|---|---|
| Loperamide | Think: OTC; P-glycoprotein keeps it out of CNS at therapeutic doses. | |
| Diphenoxylate/Atropine | Think: why is atropine added? (Schedule V controlled drug.) | |
| Bismuth subsalicylate | Think: traveler's diarrhea + avoid in children (Reye syndrome β salicylate). | |
| Octreotide | Think: somatostatin analog β VIPoma, carcinoid, variceal bleeding. | |
| Rifaximin | Think: non-absorbable β hepatic encephalopathy (β NHβ-producing flora). |
| Class | Prototype Drug(s) | Onset | MOA / Unique Fact |
|---|---|---|---|
| Bulk-Forming | Think: absorb water β β stool bulk; safest for chronic use. | ||
| Osmotic | Think: lactulose also traps NHβ in gut (hepatic encephalopathy). | ||
| Stimulant | Think: long-term use β melanosis coli (benign pigmentation). | ||
| Stool Softener | Think: surfactant β limited efficacy; prophylactic use. | ||
| Clβ» Channel Activator | Think: ClC-2 channel activator β used in IBS-C / opioid-induced constipation. | ||
| Guanylate Cyclase-C Agonist | Think: β cGMP β β Clβ»/HCOββ» secretion; for IBS-C. | ||
| PAMORA (peripheral ΞΌ-opioid antag.) | Think: excluded from CNS β doesn't reverse central analgesia. |
| Class / Drug | Target | Black Box / Key Concern |
|---|---|---|
| Anti-TNF-Ξ± (infliximab, adalimumab) | ||
| Ustekinumab | ||
| Risankizumab | ||
| Vedolizumab | ||
| Natalizumab |
Drill complete. When you've attempted every field, open the answer key and self-grade. Circle anything you missed and review the relevant lecture section.